Accueil   Agenda - News   Toutes les news EVOTEC BIOLOGICS RECEIVES GRANT TO ENABLE AN ANTIBODY PRODUCT FOR THE PREVENTION OF COVID-19

EVOTEC BIOLOGICS RECEIVES GRANT TO ENABLE AN ANTIBODY PRODUCT FOR THE PREVENTION OF COVID-19

 

  • JUST – EVOTEC BIOLOGICS RECEIVES GRANT FOR COVID-19 MONOCLONAL ANTIBODY OPTIMISATION AND CELL LINE DEVELOPMENT FROM THE COVID-19 THERAPEUTICS ACCELERATOR

 

  • GRANT ENABLES THE OPTIMISATION OF ANTI-SARS-COV-2 MAB CANDIDATES FOR DEVELOPABILITY AND LOWEST COST OF GOODS AND PROVIDES MAB DEVELOPMENT CAPACITY TO THE FOUNDATION FUNDED ENTITIES

 

Hamburg, Germany, 19 October 2020: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that its Seattle-based subsidiary, Just – Evotec Biologics, Inc., received a grant from the Bill & Melinda Gates Foundation (Seattle, WA) as part of the COVID-19 Therapeutics Accelerator to enable the development and production of monoclonal antibody (“mAb”) candidates for the prevention of severe COVID-19 in vulnerable populations in low and middle income countries.

 

 

Under the grant, Just – Evotec Biologics will use its proprietary software toolset Abacus™ to perform an in silico analysis of several lead candidate sequences of potent anti-SARS-CoV-2 mAbs provided to the foundation by several leading academic medical centres around the world. Abacus™ analysis will identify key sequences that can impact developability and, if required, make recommendations to optimise the anti-SARS-CoV-2 antibody candidates. In addition, Just – Evotec Biologics will perform cell line development for two lead molecules.

 

 

Read the press release